Dr. Schindler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4488 Forest Park Ave
Ste 160
Saint Louis, MO 63108Phone+1 314-362-1408Fax+1 314-286-1985
Summary
- Dr. Suzanne Schindler is a clinical neurologist and neuroscientist committed to improving the diagnosis and treatment of Alzheimer disease. She completed the Medical Scientist Training Program in Neurosciences, a neurology residency, and a dementia fellowship at Washington University in St. Louis. Currently Dr. Schindler sees patients with memory concerns and coordinates clinical biomarker testing for the Washington University Memory Diagnostic Center. She leads the Fluid Biomarker Core for the Knight Alzheimer Disease Research Center and facilitates many collaborative research projects. Key scientific contributions have been leading a seminal study of one of the first blood biomarkers of Alzheimer disease and developing novel approaches for understanding biomarker changes over the course of Alzheimer disease. Her current work is focused on the clinical validation of blood tests for Alzheimer disease and understanding the appropriate use of biomarker testing in the clinical diagnosis of dementia. Dr. Schindler also has a special interest in reducing healthcare disparities and improving access to diagnostic tests and treatments.
Education & Training
- Washington University/B-JH/SLCH ConsortiumResidency, Neurology, 2008 - 2012
- Washington University in St. Louis School of MedicineClass of 2008
Certifications & Licensure
- MO State Medical License 2012 - 2026
- IL State Medical License 2021 - 2023
- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Antoine Leuzy, Ariane Bollack, Daniela Pellegrino, Charlotte E Teunissen, Renaud La Joie
Alzheimer's & Dementia. 2025-03-01 - Anti-amyloid treatments: Why we think they are worth it.Suzanne E Schindler, Erik S Musiek, John C Morris
Alzheimer's & Dementia. 2025-02-24 - Associations of Cerebrospinal Fluid Orexin-A, Alzheimer Disease Biomarkers, and Cognitive Performance.Ruijin Lu, Krish Shah, Cristina D Toedebusch, Ashley Hess, Rachel Richardson
Annals of Clinical and Translational Neurology. 2025-02-17
Journal Articles
- Addressing Health Disparities Among Minority PopulationsSuzanne Schindler, MD, JAMA Neurology
Authored Content
- Blood Tests for Alzheimer’s Could Become RoutineMay 2024
Press Mentions
- Meet the New Drugs That Can Slow down Early Alzheimer’sFebruary 25th, 2025
- Alzheimer’s ‘Wonder’ Drugs Can Postpone the Move for Almost a Year, Suggests a New Study – but Experts Warn of Side EffectsFebruary 13th, 2025
- Next-Gen Alzheimer's Drugs Extend Independent Living by MonthsFebruary 13th, 2025
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: